Collegium Pharma (COLL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 258,532 | 283,749 | 269,480 | 173,688 | 134,126 |
| Marketable Securities | 46,033 | 41,721 | N/A | N/A | N/A |
| Receivables | 181,851 | 167,479 | 179,127 | 183,119 | 195,402 |
| Inventories | 34,125 | 26,026 | 32,895 | 46,501 | 64,652 |
| TOTAL | $537,086 | $537,297 | $498,300 | $419,989 | $405,216 |
| Non-Current Assets | |||||
| PPE Net | 16,645 | 18,040 | 18,879 | 19,521 | 19,744 |
| Intangibles | 590,079 | 626,396 | 663,859 | 701,163 | 739,841 |
| Other Non-Current Assets | 33,768 | 32,179 | 33,261 | 33,458 | 36,139 |
| TOTAL | $640,492 | $676,615 | $715,999 | $754,142 | $795,724 |
| Total Assets | $1,177,578 | $1,213,912 | $1,214,299 | $1,174,131 | $1,200,940 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 183,333 | 183,333 | 183,333 | 162,500 | 141,667 |
| Accounts payable and accrued liabilities | 3,653 | 2,420 | 2,992 | 3,494 | 7,637 |
| Accrued Expenses | 276,663 | 248,334 | 225,335 | 266,620 | 264,014 |
| TOTAL | $464,612 | $435,058 | $412,702 | $433,726 | $414,497 |
| Non-Current Liabilities | |||||
| Long Term Debt | 265,886 | 309,898 | 353,769 | 397,578 | 441,258 |
| Other Non-Current Liabilities | 268,207 | 268,151 | 268,095 | 147,985 | 147,991 |
| TOTAL | $534,093 | $578,049 | $621,864 | $545,563 | $589,249 |
| Total Liabilities | $998,705 | $1,013,107 | $1,034,566 | $979,289 | $1,003,746 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 32,611 | 34,734 | 34,595 | 34,067 | 33,572 |
| Common Shares | 38 | 38 | 38 | 37 | 37 |
| Retained earnings | -265,129 | -285,763 | -298,770 | -281,344 | -274,145 |
| Other shareholders' equity | 24 | 38 | 76 | 76 | -283 |
| TOTAL | $178,873 | $200,805 | $179,733 | $194,842 | $197,194 |
| Total Liabilities And Equity | $1,177,578 | $1,213,912 | $1,214,299 | $1,174,131 | $1,200,940 |